Industry | Pharmaceutical industry |
---|---|
Founded | 1996 |
Defunct | February 12, 2018 |
Fate | Acquired by Mallinckrodt |
Headquarters | Rockville, Maryland |
Key people | Peter Greenleaf (
CEO and (
Chairman) Andrew P. Smith ( CFO) |
Products | Amitiza |
Revenue | $230 million (2016) |
$18 million (2016) | |
Total assets | $520 million (2016) |
Total equity | $167 million (2016) |
Number of employees | 139 (2017) |
Website |
www |
Footnotes / references [1] |
Sucampo Pharmaceuticals, Inc. was a pharmaceutical company headquartered in Rockville, Maryland that focused on gastroenterology, ophthalmology, and oncology-related disorders. [1] In 2018, the company was acquired by Mallinckrodt.
Sucampo had two marketed products, Amitiza, which treats constipation issues and Rescula, which helps treat ocular hypertension and open-angle glaucoma. Takeda Pharmaceutical Company had a license to distribute Rescula globally except for in Japan and China. The company had two Phase III drugs in development for rare diseases — one for Niemann-Pick Type C and the other for familial adenomatous polyposis, which can cause colon cancer if untreated. [1]
The company was founded by Ryuji Ueno and Sachiko Kuno in 1996. [1]
In January 2006, the company received approval from the Food and Drug Administration for Amitiza. [2]
In 2010, the company entered into arbitration with its partner, Takeda Pharmaceutical Company, claiming that sales of Amitiza floundered because of a half-hearted marketing effort by Takeda. Sucampo lost the arbitration. [3]
In late 2015, the company moved its headquarters from Bethesda, Maryland to Rockville, Maryland. [4]
In January 2016, the company acquired an option for an exclusive license to a drug to treat familial adenomatous polyposis. [5]
In April 2017, the company acquired Vtesse. [6]
In February 2018, the company was acquired by Mallinckrodt. At that time, the founders owned a combined 30% of the company. [7]